Online Consultation For Castleman Disease Treatment Doctors in Kocaeli

Dr. Necdet Uskent is a specialized Hematologist in Turkey. And one of the most sought after medical specialists in Gebze, Turkey. The doctor has over 30+ Years of experience and is associated with Anadolu Medical Center.

Association and Memberships Dr. Necdet Uskent is part of:

• Turkish Medical Oncology Association
• Turkish Society of Hematology
• Lung Cancer Society
• Immuno-Oncology Society

Qualifications :

• Ankara University Medical School, Ankara 1971
• GATA Medical School, Ankara 1979
• Wadley Institutes of Molecular Medicine, Granville-Morton Cancer Hospital, Medical Oncology and Hematology Sub-specialties, 1982

Hospital Address :

Cumhuriyet Mahallesi, Anadolu Salk Merkezi, Cumhuriyet Cd., Gebze/Kocaeli, Turkey

What is the medical expertise of Dr Necdet Uskent?

• Dr Necdet Uskent is a leading hematologist with over 30 years of experience in treating onco hematological conditions such as lymphoma and multiple myeloma. He is competent in performing procedures like Bone marrow transplants.
• Dr Uskent is a member of several renowned organizations such as the Turkish Association of Hematology, the European Society of Medical Oncology(ESMO), the American Society of Clinical Oncology and the National Society of Medical Oncology.
• Dr Necdet completed a Fellowship in Hematology and Oncology at the University of Texas(1979-1982). Additionally, he finished Courses in Medical Oncology, at Ä°stanbul
  ( 2008 , 2009) and ESMO Courses in Antalya, Ä°stanbul, and Ankara.
• Dr Necdet serves on the Editorial Board of several journals. Some of these include the Turkish Journal of Oncology, the Turkish Journal of Hematology and Oncology and the New Drugs (International) journal.
• Over the course of his career, Dr Uskent has published more than 100 scientific articles in major journals. Some of his publications are:
  1. 1266P Prognostic significance of tumour tissue NeuGcGM3 ganglioside expression and predictive value of circulating tumour cell count monitoring in patients receiving racotumomab immunotherapy.
  2. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.
  3. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group.